ACQUISITIONS AND TRANSACTIONS (Details 2)	3 Months Ended		6 Months Ended		12 Months Ended			6 Months Ended					1 Months Ended			3 Months Ended	6 Months Ended		12 Months Ended	3 Months Ended
	Jun. 30, 2011 USD ($)		Jun. 30, 2011 USD ($)		Dec. 31, 2010 USD ($)	Jun. 30, 2010 USD ($)	Dec. 31, 2009 USD ($)	Jun. 30, 2011 Alba Therapeutics Corporation USD ($)	Feb. 28, 2011 Alba Therapeutics Corporation USD ($)	Feb. 09, 2011 Alba Therapeutics Corporation USD ($)	Jun. 30, 2011 SymBio Pharmaceuticals Limited	Feb. 28, 2011 SymBio Pharmaceuticals Limited USD ($)	Feb. 28, 2011 Mesoblast Limited USD ($)	Feb. 28, 2011 Mesoblast Limited AUD	Dec. 31, 2010 Mesoblast Limited USD ($)	Jun. 30, 2011 Mesoblast Limited USD ($)	Jun. 30, 2011 Mesoblast Limited AUD	Jun. 30, 2011 Mesoblast Limited USD ($)	Dec. 31, 2010 Mesoblast Limited AUD	Mar. 31, 2011 Mepha GmbH USD ($)	Jun. 30, 2011 United States USD ($)	Dec. 31, 2010 United States USD ($)
Acquisitions and transactions
Upfront option payment made under the terms of the option agreement									$ 7,000,000
Stock price (in dollars per share)			$ 79.90		$ 61.72
Stock price of the acquiree (in dollars per share)														5.57			8.65		4.67
Credit facility provided under the terms of the option agreement									22,000,000
Purchase price of assets if the entity exercises the option under the option agreement									15,000,000
Loans provided under the credit facility								10,000,000
Loss recognized on deconsolidation if the option expires unexercised								7,000,000
Purchase price of additional common shares												9,400,000
Percentage interest held in cost basis investment (as a percent)											18.50%
Nonrefundable up front payment agreed to be paid as part of a development and commercialization agreement															130,000,000
Acquired in process research and development expense	0		30,000,000										30,000,000		100,000,000
Payment for acquisition of equity interest													109,100,000		133,900,000
Percentage of investment (as a percent)													7.80%	7.80%	12.20%	20.00%	20.00%	20.00%
Fair value of equity interest acquired													138,100,000		145,900,000	505,800,000		505,800,000
Change in fair value of investments	99,473,000		264,208,000													91,200,000		250,800,000
Cash payments to be made upon the achievement of certain regulatory and sales milestones																1,700,000,000		1,700,000,000
Number of indications in various territories as basis for estimation of milestone payments																10	10	10
Adjustment to goodwill from acquisition accounting for certain tax liabilities			2,989,000																	3,000,000
Carrying amounts and classification of Alba's assets and liabilities included in consolidated balance sheet
Cash and cash equivalents	997,476,000	[1]	997,476,000	[1]	1,160,239,000	927,446,000	1,647,635,000	9,890,000		15,513,000
Other current assets	98,272,000	[1]	98,272,000	[1]	54,845,000			168,000		45,000
Property and equipment, net	507,152,000	[1]	507,152,000	[1]	502,856,000			18,000		4,000
Goodwill	866,272,000	[1]	866,272,000	[1]	822,071,000			2,118,000		2,118,000											493,091,000	486,619,000
Intangible assets	1,724,246,000	[1]	1,724,246,000	[1]	1,212,387,000			40,000,000		40,000,000
Current portion of long-term debt, net								3,560,000		3,560,000
Accounts payable	120,128,000	[1]	120,128,000	[1]	104,477,000			586,000		3,167,000
Accrued expenses	479,080,000	[1]	479,080,000	[1]	460,141,000			1,159,000		953,000
Noncontrolling Interest	$ 79,495,000	[1]	$ 79,495,000	[1]	$ 34,160,000			$ 29,797,000		$ 33,000,000

[1] Amounts include assets and liabilities of our variable interest entities (VIEs). Our interests and obligations with respect to VIEs' assets and liabilities are limited to those accorded to us in our agreements with our VIEs. See Note 2 to these consolidated financial statements for amounts.